Sirolimus by OrphAI Therapeutics for Bronchiolitis Obliterans: Likelihood of Approval

Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Bronchiolitis Obliterans.

Source link
#Sirolimus #OrphAI #Therapeutics #Bronchiolitis #Obliterans #Likelihood #Approval